Since its formal inauguration as a Health Research Institute in 2010, INCLIVA has made remarkable strides arising from its research activity. Especially noteworthy are its 8 patents and its 2 registered software programs, as well as the 2 spin-off companies which developed from research conducted at INCLIVA
INNOVATION POLICY : download
TECHNOLOGY-BASED SPIN-OFF COMPANIES:
Seqplexing is a company created in 2013 borne from the idea of generating solutions for research and clinical applications, based on introducing new techniques and advanced genomic platforms, especially next-generation sequencing (NGS). Seqplexing aims to cover the need for reliable protocols for sequencing amplicons or genes. To do this, they developed closed solutions in their laboratories that are easy to use and implement.
Seqplexing’s mission focuses on providing a service to laboratories who do not have time to develop appropriate protocols for sequencing genes or regions of interest as part of their normal work routine. Seqplexing is transforming all of the elements required to carry out these techniques into commercial kits, providing a comprehensive service from the start of sample preparation to the final analysis of the results.
Epidisease was created in 2014 as the result of a project led by INCLIVA researchers and the Centre of Networked Biomedical Research (CIBER; Centro de Investigación Biomédica en Red) in Rare Diseases in order to transfer epigenetics and biomedical sciences knowledge to the service of society.
The epigenetics field studies all the factors and mechanisms involved in controlling gene expression. The importance of this science is growing, as evidenced by some of the findings of the Human Genome Project, through which scientists realized that the molecular basis of cell function, development, aging, and many illnesses goes far beyond only DNA sequences. Recent findings from the Epigenome Road Map project are also proof of this.
Epidisease’s mission is to leverage its expertise in the field of epigenetics to provide its customers with biomedical solutions, diagnostic tools, and new therapies, as well as to stimulate translational research with the aim of improving people’s health and welfare.
Nela BioDynamics is a young technology development company in biomedicine, which arises from the Valencian university collaboration, formed by a group of multidisciplinary researchers who are experts in biomedicine and engineering. The company arises from the results of a Final Master's Thesis in Biomedical Engineering, which lead to the obtaining of two patents on a novel intramedullary fixation system for joint endoprosthesis, nails for fractures and exoprosthesis; and a percutaneous ostomy collar.
The modular NELA implant allows for a customized fit to each patient and avoids the conventional techniques based on impact press-fit or use bone cement to achieve the fixation. All this translates into shorter surgery times, less pain, higher success rates and better quality of life for the patient.
The NELA’s solution will allow us to respond to different unsolved medical needs, also providing a positive socio-economic impact.
ARTHEx BIOTECH is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases. The team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. They are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of their products.
Our main objective is finding effective treatments to unmet medical needs. The first target of the company will be to investigate anti-microRNAs for the treatment of myotonic dystrophy Type 1 (DM1), which is an orphan disease affecting more than 900.000 people worldwide (estimated prevalence 1/8000).